A Product and Pipeline Analysis of the Opioid Therapeutics and Drug Delivery Market
A Product and Pipeline Analysis of the Opioid Therapeutics and Drug Delivery Market
RELEASE DATE
02-Mar-2015
02-Mar-2015
REGION
North America
North America
Research Code: NED9-01-00-00-00
SKU: LS00133-NA-MR_16974
$3,950.00
In stock
SKU
LS00133-NA-MR_16974
Description
This market insight provides data for the Global Opioid Therapeutics market. The analysis looks at opioid pharmaceutical pipeline drugs currently in the market and drugs that are in Phase III stage, which pose a potential threat to competitors. It also offers a competitive analysis of the drugs, and the forecast outcome and impact of each of these drugs. Opioid drugs in the current market have a space for tamper-resistant formulations. The opioids market is segmented into relapsing neuropathic pain, acute and post-operative pain, cancer-induced pain, and moderate to severe chronic pain.
Table of Contents
Methodology and Scope
Executive Summary
Executive Summary (continued)
Executive Summary (continued)
Executive Summary (continued)
Executive Summary (continued)
Executive Summary (continued)
Executive Summary (continued)
Introduction
Physician Guidelines to Opioid Therapy—Moderate to Severe Chronic Pain
Physician Guidelines to Opioid Therapy—Neuropathic Pain
Physician Guidelines to Opioid Therapy—Cancer-induced Pain
Physician Guidelines to Opioid Therapy—Acute and Post-operative Pain
Introduction—Chronic Pain Prevalence by Severity
Opioid Pain Market by Region
Top-selling Products in the US Opioid Therapeutics Market
Opioid Therapeutics—Percent Sales by Type of Pain
Opioid Therapeutics—Pain Formulation Prescription Sales
Opioid Therapeutics—TRF and Non-TRF Prescription Sales
Opioid Therapeutics—Estimated Peak Sales by Route of Administration
Opioid Therapeutics Market—Pain Patch Products
Game-changing Strategies
Companies to Watch
Opioid Therapeutics Market—Competitive Landscape
Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market
Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)
Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)
Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)
Marketed Product Synopsis—Moderate to Severe Chronic Pain Opioid Therapeutics Market (continued)
Pipeline Analysis—Moderate to Severe Chronic Pain Opioid Therapeutics
Pipeline Analysis—Moderate to Severe Chronic Pain Opioid Therapeutics (continued)
Pipeline Analysis—Moderate to Severe Chronic Pain Opioid Therapeutics (continued)
Marketed Product—Neuropathic Pain Opioid Therapeutics
Pipeline Analysis—Neuropathic Pain Opioid Therapeutics
Pipeline Analysis—Neuropathic Pain Opioid Therapeutics (continued)
Marketed Product Synopsis—Cancer-induced Pain Opioid Therapeutics
Marketed Product Synopsis—Cancer-induced Pain Opioid Therapeutics (continued)
Pipeline Analysis—Cancer-induced Pain Opioid Therapeutics
Marketed Product Synopsis—Post-operative and Acute Pain Opioid Therapeutics
Pipeline Analysis—Post-operative and Acute Pain Opioid Therapeutics
Moderate to Severe Chronic Pain Clinical Trial Design Comparison—Phase 3
Moderate to Severe Chronic Pain Clinical Trial Design Comparison—Phase 3 (continued)
Moderate to Severe Chronic Pain Clinical Trial Design Comparison—Phase 3 (continued)
Cancer-induced Pain Clinical Development Synopsis—Phase 3
Post-operative and Acute Pain Clinical Trial Design Comparison—Phase 3
Estimated US Product Launch Timeline
Pre-launch Products Clinical Program—Remoxy and HYD Tablets
Pipeline Products Clinical Phase 3 Studies—BEMA Buprenorphine, COL-003, Nucynta
Pipeline Products Clinical Phase 3 Studies—Zalviso
Product Dashboard: Remoxy (Durect/Pain Therapeutics)
Product Dashboard: BEMA Buprenorphine (Endo Pharmaceuticals/Biodelivery)
Product Dashboard: HYD Tablet (Purdue Pharma)
Product Dashboard: COL-003/Oxycodone DETERx (Collegium)
Product Dashboard: Nucynta Extended Release (Grünenthal/J&J)
Product Dashboard: MoxDuo Immediate Release (Actavis/QRxPharma)
The Last Word
Legal Disclaimer
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
This market insight provides data for the Global Opioid Therapeutics market. The analysis looks at opioid pharmaceutical pipeline drugs currently in the market and drugs that are in Phase III stage, which pose a potential threat to competitors. It also offers a competitive analysis of the drugs, and the forecast outcome and impact of each of these drugs. Opioid drugs in the current market have a space for tamper-resistant formulations. The opioids market is segmented into relapsing neuropathic pain, acute and post-operative pain, cancer-induced pain, and moderate to severe chronic pain.
No Index | No |
---|---|
Podcast | No |
WIP Number | NED9-01-00-00-00 |
Is Prebook | No |